Adma Biologics

ADMA

10.3101.28% ( +0.130 )

Closed: Oct 13, 16:00:00 (EDT)

Current ValuationThe current P/E ratio is 13.67, within the reasonable range, cheaper than 57.47% of the time in the past 1 years, and the industry ranks 35/604, the industry Median -2.00.

13.67xP/E

Stock price$10.31Earnings per share$0.75

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

020406080

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	13.65x	68.61%	$22.02B
GRFSUSGRIFOLS SA	9.41x	42.44%	$4.93B
ACADUSAcadia Pharma	8.43x	73.60%	$3.21B
ADMAUSAdma Biologics	13.67x	35.42%	$2.31B
NRIXUSNurix Therapeutics	7.79x	181.97%	$2.30B
AUPHUSAurinia Pharma	6.93x	54.40%	$2.18B
PURRUSHyperliquid Strategies	7.90x	67.60%	$2.02B
LKFTUSLakefront Biotherapeutics	2.73x	86.27%	$1.89B
ANABUSAnaptysbio	5.20x	1,003.56%	$1.36B
VORUSVor BioPharma	1.80x	89.77%	$1.13B
MGTXUSMeiraGTx	12.09x	122.03%	$954.67M
BVNRYUSBavarian Nordic A/S	3.72x	--	$891.52M
RIGLUSRigel Pharma	2.74x	83.91%	$880.57M
ABUSUSArbutus Pharma	5.29x	535.59%	$809.42M
IRWDUSIronwood Pharma	4.57x	715.55%	$593.21M
AGENUSAgenus	3.41x	--	$312.89M
CUVLUSClinuvel Pharmaceuticals	11.95x	--	$274.43M
QTTBUSQ32 Bio	7.10x	162.04%	$239.94M
PLXUSProtalix Biotherap	11.70x	400.00%	$221.57M
CGENUSCompugen	5.33x	173.68%	$187.55M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.